![conference banner](/images/conference-banner.jpeg)
Abstract
The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Current Topics in Medicinal Chemistry
Title:A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology
Volume: 12 Issue: 15
Author(s): C. Faivre, D. Barbolosi and A. Iliadis
Affiliation:
Keywords: MTD, DLT, CRM, Toxicity grades, Skewed Logistic, MCMC methods, Prior distributions
Abstract: The primary goal of phase I studies in oncology is to determine the MTD (Maximum Tolerated Dose) for a drug. This MTD is determined with respect to an accepted risk (usually 33%) to see a limiting toxity for patients. In this paper we propose a new mathematical model to determine the MTD. An important feature of this model is that the limiting toxicity can be formulated as a combination of several basic graded toxicities such as hematologic or neurological. Another feature is the possibility to take into account several patient covariates to individualize the determination of the MTD. The model is a bayesian model where some prior information has been considered. The model is expected to work better than traditional empirical schemes for determining the MTD because it uses at every step all the available information on patients, and adds some major improvements as compared with existing CRM strategies because it uses whole data made available, including low-grades toxicities. Finally the model has been validated with a retrospective data set on 17 patients from a phase I study on paclitaxel in pediatric oncology. Calculated MTDs for each patient were found to be markedly different than the doses actually given following a traditionnal dose-escalation methodology. Results suggest that our new model provides a better and safer way to drive dose-escalation in phase-I trials as compared with traditionnal schemes.
Export Options
About this article
Cite this article as:
Faivre C., Barbolosi D. and Iliadis A., A New Model for Determining the MTD During Phase-I Trials in Pediatric Oncology, Current Topics in Medicinal Chemistry 2012; 12 (15) . https://dx.doi.org/10.2174/156802612803531469
DOI https://dx.doi.org/10.2174/156802612803531469 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy Efficacy of Cannabis and its Constituents in Disease Management: Insights from Clinical Studies
Current Medicinal Chemistry Drug Repositioning for Treatment of Movement Disorders: From Serendipity to Rational Discovery Strategies
Current Topics in Medicinal Chemistry Role of Nanotechnology for Enzyme Replacement Therapy in Lysosomal Diseases. A Focus on Gaucher’s Disease
Current Medicinal Chemistry Nanocarrier based Antiretroviral Drug Delivery Approaches
Pharmaceutical Nanotechnology Editorial [Hot Topic: Novel and Emerging Drugs for Leukemias (Guest Editor: Tadeusz Robak)]
Current Cancer Drug Targets Cell Cycle Kinases in Osteosarcoma: Potential for Therapeutic Intervention
Current Pharmaceutical Design The Synthesis of Risedronic Acid and Alendronate Applying Phosphorus Oxychloride and Phosphorous Acid in Methanesulfonic Acid
Letters in Drug Design & Discovery Dietary Additive Probiotics Modulation of the Intestinal Microbiota
Protein & Peptide Letters Interview: Dr. Muin J. Khoury Discusses the Future of Public Health Genomics and why it Matters for Personalized Medicine and Global Health
Current Pharmacogenomics and Personalized Medicine Prematurely Aged Children: Molecular Alterations Leading to Hutchinson-Gilford Progeria and Werner Syndromes
Current Aging Science Heme Oxygenase-1 as a Target for the Design of Gene and Pharmaceutical Therapies for Autoimmune Diseases
Current Gene Therapy Revision of QSAR, Docking, and Molecular Modeling Studies of Anti-Influenza Virus A (H1N1) Drugs and Targets: Analysis of Hemagglutinins 3D Structure
Current Computer-Aided Drug Design Cystic Fibrosis: New Insights into Therapeutic Approaches
Current Respiratory Medicine Reviews Amphotericin B: From Derivatives to Covalent Targeted Conjugates
Mini-Reviews in Medicinal Chemistry The Toolbox of Designing Nanoparticles for Tumors
Mini-Reviews in Medicinal Chemistry Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews